Psychiatria polska
June 30, 2024
Piotr Gałecki, Katarzyna Maria Bliźniewska-Kowalska, Wiesław Jerzy Cubała et al.
5 citations
A Polish expert panel developed national treatment standards for intravenous racemic ketamine in depressive disorders, addressing the one-third of depressed patients who do not respond to standard antidepressants. The guidelines summarize research on ketamine's efficacy and safety for unipolar and bipolar depression, leveraging its action as an NMDA receptor antagonist to modulate the overactive glutamatergic system implicated in depression. The recommendations cover indications, contraindications, precautions, and treatment protocols, aiming to expand therapeutic options for practicing psychiatrists.
Medical Science Monitor
June 30, 2025
Andrzej Silczuk, Robert Madejek, Tytus Koweszko et al.
4 citations
Psychedelics, meaning 'soul-revealing', are classified into hallucinogens (LSD, psilocybin, mescaline), entactogens (MDMA), and dissociatives (PCP, ketamine). The idea of using them in psychotherapy emerged in the 1940s, and after a period of restricted research, modern investigations resumed about 20 years ago. This review of the last decade finds that psychedelic-assisted psychotherapy remains experimental. Preliminary studies suggest potential benefits for depression, post-traumatic stress disorder, obsessive-compulsive disorder, and substance use disorders, but a definitive assessment is limited by a scarcity of large-scale, rigorous clinical trials. Psychedelics should be viewed as components of broader therapeutic frameworks, not standalone treatments. Their effect on neuroplasticity may address treatment gaps for patients unresponsive to conventional methods, but this requires validation through larger, randomized, double-blind, placebo-controlled trials.
Frontiers in psychiatry
January 1, 2024
Magdalena Więdłocha, Piotr Marcinowicz, Jan Komarnicki et al.
4 citations
Borderline personality disorder (BPD) occurs in 10-30% of patients with major depressive disorder (MDD), and over 80% of individuals with BPD also have MDD. This comorbidity leads to more severe depression, greater functional impairment, higher treatment resistance, and increased suicidality. While ketamine effectively treats treatment-resistant depression (TRD), existing studies often did not exclude people with BPD, suggesting benefits may extend to those with both conditions. However, no protocols specifically address this comorbidity, and psychotherapeutic interventions crucial for lasting effects have been omitted.
Frontiers in psychiatry
January 1, 2024
Magdalena Więdłocha, Piotr Marcinowicz, Jan Komarnicki et al.
1 citation
correction
No Summary
Frontiers in neuroscience
January 1, 2024
Weronika Dębowska, Magdalena Więdłocha, Marta Dębowska et al.
correction
A corrigendum corrects errors in a previously published article on transcranial magnetic stimulation and ketamine for depression. The original funding statement displayed an incorrect grant number; the correct number is "Key Development Project of Department of Science and Technology (2015C03Bd051)." Additionally, the original Conflict of Interest statement omitted that two co-authors were employed by KeyClinic, a commercial mental health center offering ketamine and TMS treatment among other services, and one author was employed by Mind Health, served on the Janssen Cilag Advisory Board, and gave lectures for Janssen Cilag.